Pherecydes Pharma announces the appointment of Dr Pascal Birman as Medical Director
NANTES, France – (COMMERCIAL THREAD) – Regulatory news:
Pherecides Pharma (Paris: ALPHE) (FR0011651694 – ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and / or complicated bacterial infections, today announces the appointment of Dr Pascal Birman as Medical Director.
Dr Pascal Birman will bring to Pherecydes Pharma his 30 years of experience in medical research and pharmaceutical development, particularly in endocrinology and metabolic diseases. After a career as a doctor at AP-HP Parisian university hospital network (1981-1990), he joined the Servier group as International project manager before taking up managerial positions as a Director of Therapeutic Research and Director of International Clinical Operations Europe-Asia. In 2004, Dr Birman joined the pharmaceutical group Ipsen, where he held various positions for 13 years including Vice-President of Global Clinical Development Programs.
Before joining Pherecydes Pharma, Dr Birman was Deputy Chief Physician within the biopharmaceutical company Genfit, a position he has held since 2018. At Pherecydes Pharma, he replaces Dr Brigitte Palestro, who will continue to support and assist the Company until his retirement in January 2022.
Guy-Charles Fanneau de La Horie, Chairman of the Management Board of Pherecydes Pharma, says: “I am delighted that such a recognized expert as Dr Pascal Birman has accepted to join the Pherecydes Pharma teams as Medical Director, a position that has always been at the heart of our Company. I would also like to warmly and sincerely thank Dr Brigitte Palestro for her major contribution to the development of Pherecydes Pharma in recent years. All our teams are enthusiastic about this new collaboration as we prepare for the ramp-up of our activity, with the upcoming launch of several clinical studies with our phages and the availability of these as part of AAC early access programs.”.
About Pherecydes Pharma
Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural viruses that kill bacteria. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone represent more than two thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of precision phage therapy has been successfully applied to several dozen patients in the context of compassionate use, under the control of the National Medicines Safety Agency (ANSM). Based in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, the biotechnology sector and academic research.
For more information, www.pherecydes-pharma.com
This press release contains non-factual elements including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current vision and assumptions of the management of the Company. They incorporate known and unknown risks and uncertainties that could lead to significant differences in results, profitability and expected events. In addition, Pherecydes Pharma, its shareholders and its affiliates, directors, officers, advisers and employees have not verified the accuracy and make no representations or warranties regarding the statistical information or forward-looking information contained in this press release and which originate or are derived from third party sources or industry publications; these statistical data and forecast information are used in this press release for informational purposes only. Finally, this press release may be written in French and in English. In the event of discrepancies between the two texts, the French version will prevail.